VYNE Therapeutics to Showcase Innovations at Key Conference

Author: Addison Perry Updated: 03-20-2025 08:19 AM

VYNE Therapeutics Announces Participation in Vital Conference

BRIDGEWATER, N.J. — VYNE Therapeutics Inc. (Nasdaq: VYNE), a clinical-stage biopharmaceutical firm, is excited to share news of its upcoming participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. This event will take place on March 27, 2025, providing a platform for in-depth discussions on pivotal advancements in treating chronic inflammatory conditions.

Insights from VYNE’s Management

VYNE’s management team will engage with attendees, offering valuable insights into their innovative therapies aimed at addressing high unmet medical needs in autoimmune and inflammatory diseases. This conference will serve as a conduit for communicating their progress and unique treatment methodologies.

Conference Presentation Details

This virtual event will feature a Fireside Chat, where VYNE will discuss its groundbreaking research and the potential impact of its product pipeline on the healthcare landscape. The chat is scheduled for 11:00 am ET on March 27, 2025.

How to Participate

For those interested in joining the Fireside Chat, further details will be available through the official conference platform. It is anticipated that the session will provide ample opportunity for queries and engagement regarding VYNE's research initiatives.

Webcast Replay Available

Following the event, a replay of the webcast will be accessible on the VYNE website for 90 days. This allows stakeholders and interested parties to revisit the insights shared and the discussions that took place during the conference.

About VYNE Therapeutics Inc.

VYNE Therapeutics is committed to developing tailored and effective therapies to battle chronic inflammatory and immune-mediated conditions that affect countless individuals. Their InhiBET™ platform features proprietary BET inhibitors, specifically designed to improve upon earlier generational therapies by utilizing alternative administration routes and achieving greater selectivity.

Investor and Media Relations

For further inquiries or information regarding VYNE Therapeutics and its innovative solutions, direct communication channels are available:

Investor Relations Contacts:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

Media Relations Contacts:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com

Frequently Asked Questions

What is the main focus of VYNE Therapeutics?

VYNE Therapeutics is centered on developing therapies for chronic inflammatory and immune-mediated conditions.

When will VYNE participate in the conference?

The participation is scheduled for March 27, 2025, at 11:00 am ET.

How can I access the webcast replay?

The webcast replay will be available on the VYNE website for 90 days post-event.

What is the InhiBET™ platform?

The InhiBET™ platform is VYNE's proprietary system of BET inhibitors aimed at overcoming earlier generation treatment limitations.

Who can be contacted for investor inquiries?

Investor inquiries can be directed to John Fraunces or Tyler Zeronda at VYNE Therapeutics.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.